T 0419/16 (IL-33 antagonist antibodies/MSD) of 03.02.2022

European Case Law Identifier: ECLI:EP:BA:2022:T041916.20220203
Date of decision: 3 February 2022
Case number: T 0419/16
Petition for review of: -
Application number: 05713577.4
IPC class: A61K 38/17 C07K 16/28 C07K 16/24 A61P 25/02 A61P 37/00 A61P 11/06 A61P 35/00 A61K 38/20 A61K 39/395 A61P 19/02 C07K 14/715 A61P 31/00
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: T 0419/16 IL-33 antagonist antibody/MERCK SHARP & DOHME 2024-06-24
Abstracts for this decision: -
Application title: Use for Interleukin-33 (IL-33) and the IL-33 Receptor Complex
Applicant name: Merck Sharp & Dohme LLC
Opponent name: Regeneron Pharmaceuticals, Inc.
Strawman Limited
Gray, Tony
Takeda California, Inc.
Sanofi
Board: 3.3.04
Headnote: -
Relevant legal provisions: European Patent Convention Art 123(2)European Patent Convention Art 54 European Patent Convention Art 83 European Patent Convention Art 87(1)
Keywords: Amendments - main request
Amendments - added subject-matter (yes)
Amendments - auxiliary request 1
Amendments - added subject-matter (no)
Sufficiency of disclosure - auxiliary request 1 (yes)
Priority - auxiliary request 1
Priority - same invention (yes)
Stay of proceedings (yes) - questions on entitlement to priority pending before the Enlarged Board
Catchword: -
Cited cases: G 0005/83 G 0002/10 T 0128/82 T 0036/83 T 0426/00 T 1513/17 T 2719/19
Citing cases: G 0001/22 G 0002/22 T 0419/16 T 1513/17 T 2719/19

Order

For these reasons it is decided that:

1. Opponent 2's appeal is rejected as inadmissible and the request for reimbursement of the appeal fee is rejected.

2. The appeal proceedings are stayed until a decision is issued by the Enlarged Board of Appeal in cases G 1/22 and G 2/22. They will be continued in writing thereafter.